Charles Thomas Smith Ii, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23355 5th Ave, Florala, AL 36442 Phone: 334-858-3291 Fax: 334-858-5254 |
Dr. William Taylor Benton Iii, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23355 5th Ave, Florala, AL 36442 Phone: 334-858-3291 Fax: 334-858-5254 |
Samantha E Caton, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23355 5th Ave, Florala, AL 36442 Phone: 334-858-3292 Fax: 334-858-5254 |
Dr. Magen Adams, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23355 5th Ave, Florala, AL 36442 Phone: 334-858-3291 |
Miss Jessica Renee Fowler, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23355 5th Ave, Florala, AL 36442 Phone: 334-858-3291 Fax: 334-858-5254 |
Mr. Thomas Kevin Frye, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23355 5th Ave, Florala, AL 36442 Phone: 334-858-3291 Fax: 334-858-5254 |
News Archive
Adopting a Mediterranean-style eating pattern improves heart health, with or without reducing red meat intake, if the red meat consumed is lean and unprocessed, according to a Purdue University nutrition study.
New research led by Wyss Core Faculty member David Mooney, Ph.D., in collaboration with researchers at the Dana-Farber Cancer Institute could potentially yield a new platform for cancer vaccines. Leveraging a biologically inspired sponge-like gel called "cryogel" as an injectable biomaterial, the vaccine delivers patient-specific tumor cells together with immune-stimulating biomolecules to enhance the body's attack againstcancer.
Parents of nut-allergy sufferers face hostility and scepticism in trying to find safe environments for their children, a new study has found.
Many states permit the use of medical marijuana. Now there's evidence that pot might work as "marital marijuana," revving up sex drives in both men and women.
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
› Verified 4 days ago